Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

745
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
745
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

622
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
622
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.9K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

716
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
716

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atherogenic Index of Plasma and Atypical Lipid Indicators as a Predictor of Nonalcoholic Fatty Liver Disease in Nonobese Individuals.

Annals of African medicine·2026
Same author

Examining the impact of artificial intelligence on physicians' performance: mediating effects of innovative work behavior and skills enhancement.

Journal of health organization and management·2026
Same author

Etiopathogenesis and Current Management of Oncogenic Pruritus - A Narrative Review.

Indian journal of dermatology·2025
Same author

Advanced generative adversarial network for optimizing layout of wireless sensor networks.

Scientific reports·2024
Same author

India Unburdening the Pandemic: Jabs and Talks.

Cureus·2023
Same author

Comparison of Framingham Risk Scores (FRS), Joint British Society (JBS3), and American College of Cardiology/American Heart Association (ACC/AHA) Cardiovascular Risk Scores Among Adults With First Myocardial Infarction.

Cureus·2023

Related Experiment Video

Updated: Mar 20, 2026

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

12.6K

Antituberculous Therapy-Induced Rare Skin Toxicity: Bullous Pemphigoid.

Reshma C Patil1, Vishwanath Krishnamurthy1, Divya Prabhu1

  • 1Department of General Medicine, M. S. Ramaiah Medical College Hospital, Bengaluru, Karnataka, India.

Journal of Pharmacy & Bioallied Sciences
|March 19, 2026
PubMed
Summary

Bullous pemphigoid (BP) is a rare autoimmune blistering disease. Antituberculous therapy (ATT) can trigger BP, necessitating early drug withdrawal for patient recovery.

Area of Science:

  • Dermatology
  • Autoimmunology
  • Pharmacology

Background:

  • Bullous pemphigoid (BP) is a chronic autoimmune blistering skin disease.
  • Antituberculous therapy (ATT) is rarely associated with BP development.
Keywords:
Antitubercular therapyBullous pemphigoidblistering disorderdrug-inducedskin toxicity

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

11.0K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

11.2K

Related Experiment Videos

Last Updated: Mar 20, 2026

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

12.6K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

11.0K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

11.2K